This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: University of Michigan. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Maria Chiara Magnone: Innovator in Chronic Kidney Disease Research
Introduction
Maria Chiara Magnone is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of chronic kidney disease (CKD) through her innovative research and patented technologies. Her work focuses on identifying biomarkers that can predict the progression of CKD, which is crucial for improving patient outcomes.
Latest Patents
Maria Chiara Magnone holds a patent for "Biomarkers and methods for progression prediction for chronic kidney disease." This invention involves the detection of levels of various biomarkers, including NTpro BNP, EGF, Apo H, GDF-15, and the albumin-to-creatinine ratio. These biomarkers are essential for assessing the risk of CKD progression and for monitoring therapy effectiveness.
Career Highlights
Maria Chiara Magnone is affiliated with the University of Michigan, where she continues her research in the field of kidney disease. Her work has garnered attention for its potential to transform how chronic kidney disease is diagnosed and treated. With her innovative approach, she aims to enhance the quality of life for patients suffering from this condition.
Collaborations
Maria Chiara Magnone collaborates with esteemed colleagues, including Laura Badi and Martina Thier. These partnerships foster a dynamic research environment that encourages the exchange of ideas and advancements in CKD research.
Conclusion
Maria Chiara Magnone's contributions to chronic kidney disease research through her patented innovations highlight her role as a leading inventor in the medical field. Her work not only advances scientific understanding but also has the potential to significantly impact patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile